WO2003045318A3 - Manipulation of cytokine levels using cd83 gene products - Google Patents

Manipulation of cytokine levels using cd83 gene products Download PDF

Info

Publication number
WO2003045318A3
WO2003045318A3 PCT/US2002/037738 US0237738W WO03045318A3 WO 2003045318 A3 WO2003045318 A3 WO 2003045318A3 US 0237738 W US0237738 W US 0237738W WO 03045318 A3 WO03045318 A3 WO 03045318A3
Authority
WO
WIPO (PCT)
Prior art keywords
cytokine levels
manipulation
gene products
immune system
gene
Prior art date
Application number
PCT/US2002/037738
Other languages
French (fr)
Other versions
WO2003045318A2 (en
Inventor
Fred Ramsdell
Sean C Proll
Karen Staehling-Hampton
Mark W Appelby
Leon Fernando Garcia Martinez
Original Assignee
Celltech R & D Inc
Fred Ramsdell
Sean C Proll
Karen Staehling-Hampton
Mark W Appelby
Leon Fernando Garcia Martinez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R & D Inc, Fred Ramsdell, Sean C Proll, Karen Staehling-Hampton, Mark W Appelby, Leon Fernando Garcia Martinez filed Critical Celltech R & D Inc
Priority to JP2003546823A priority Critical patent/JP2005519586A/en
Priority to CA002466845A priority patent/CA2466845A1/en
Priority to AU2002357759A priority patent/AU2002357759A1/en
Priority to EP02792297A priority patent/EP1480598A4/en
Priority to US10/496,284 priority patent/US7618629B2/en
Publication of WO2003045318A2 publication Critical patent/WO2003045318A2/en
Priority to AU2003300817A priority patent/AU2003300817A1/en
Priority to EP03812060A priority patent/EP1572976B1/en
Priority to EP10168125A priority patent/EP2258724A1/en
Priority to US10/719,642 priority patent/US20040185040A1/en
Priority to DE60334246T priority patent/DE60334246D1/en
Priority to AT03812060T priority patent/ATE481422T1/en
Priority to PCT/US2003/038599 priority patent/WO2004048552A2/en
Publication of WO2003045318A3 publication Critical patent/WO2003045318A3/en
Priority to US11/805,841 priority patent/US7700740B2/en
Priority to US12/572,592 priority patent/US7850968B2/en
Priority to US12/699,636 priority patent/US7872103B2/en
Priority to US12/941,689 priority patent/US20110144309A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention provides methods for modulating cytokine levels, GM-CSF levels and the immune system using CD83 nucleic acids, CD83 polypeptides, anti-CD83 antibodies and factors that influence CD83 activity or expression. The invention also provides mice having a mutant CD83 gene and mice having a transgenic CD83 gene, which are useful for defining the role of CD83 in the immune system and for identifying compounds that can modulate CD83 and the immune system.
PCT/US2002/037738 2001-11-21 2002-11-21 Manipulation of cytokine levels using cd83 gene products WO2003045318A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
JP2003546823A JP2005519586A (en) 2001-11-21 2002-11-21 Cytokine level manipulation method using CD83 gene product
CA002466845A CA2466845A1 (en) 2001-11-21 2002-11-21 Manipulation of cytokine levels using cd83 gene products
AU2002357759A AU2002357759A1 (en) 2001-11-21 2002-11-21 Manipulation of cytokine levels using cd83 gene products
EP02792297A EP1480598A4 (en) 2001-11-21 2002-11-21 Manipulation of cytokine levels using cd83 gene products
US10/496,284 US7618629B2 (en) 2001-11-21 2002-11-21 Manipulation of cytokine levels using CD83 gene products
PCT/US2003/038599 WO2004048552A2 (en) 2002-11-21 2003-11-21 Modulating immune responses
EP03812060A EP1572976B1 (en) 2002-11-21 2003-11-21 Modulating immune responses
AU2003300817A AU2003300817A1 (en) 2002-11-21 2003-11-21 Modulating immune responses
EP10168125A EP2258724A1 (en) 2002-11-21 2003-11-21 Modulating immune responses using multimerized anti-CD83 antibodies
US10/719,642 US20040185040A1 (en) 2001-11-21 2003-11-21 Modulating immune responses
DE60334246T DE60334246D1 (en) 2002-11-21 2003-11-21 MODULATE IMMUNE RESPONSES
AT03812060T ATE481422T1 (en) 2002-11-21 2003-11-21 MODULATING IMMUNE RESPONSES
US11/805,841 US7700740B2 (en) 2001-11-21 2007-05-23 Antibodies to CD83
US12/572,592 US7850968B2 (en) 2001-11-21 2009-10-02 Manipulation of cytokine levels using CD83 gene products
US12/699,636 US7872103B2 (en) 2001-11-21 2010-02-03 Modulating immune responses
US12/941,689 US20110144309A1 (en) 2001-11-21 2010-11-08 Manipulation of Cytokine Levels Using CD83 Gene Products

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33195801P 2001-11-21 2001-11-21
US60/331,958 2001-11-21

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10496284 A-371-Of-International 2002-11-21
US10/719,642 Continuation US20040185040A1 (en) 2001-11-21 2003-11-21 Modulating immune responses
US12/572,592 Continuation US7850968B2 (en) 2001-11-21 2009-10-02 Manipulation of cytokine levels using CD83 gene products

Publications (2)

Publication Number Publication Date
WO2003045318A2 WO2003045318A2 (en) 2003-06-05
WO2003045318A3 true WO2003045318A3 (en) 2004-09-16

Family

ID=23296083

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/037738 WO2003045318A2 (en) 2001-11-21 2002-11-21 Manipulation of cytokine levels using cd83 gene products

Country Status (6)

Country Link
US (3) US7618629B2 (en)
EP (1) EP1480598A4 (en)
JP (1) JP2005519586A (en)
AU (1) AU2002357759A1 (en)
CA (1) CA2466845A1 (en)
WO (1) WO2003045318A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8992908B2 (en) 2010-11-23 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of oral mucositis
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8999330B2 (en) 2007-05-21 2015-04-07 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9085615B2 (en) 2008-11-25 2015-07-21 Alderbio Holdings Llc Antibodies to IL-6 to inhibit or treat inflammation
US9187560B2 (en) 2008-11-25 2015-11-17 Alderbio Holdings Llc Antagonists of IL-6 to treat cachexia, weakness, fatigue, and/or fever
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9241990B2 (en) 2007-05-21 2016-01-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRIP
US9265825B2 (en) 2008-11-25 2016-02-23 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US9468676B2 (en) 2009-11-24 2016-10-18 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9546213B2 (en) 2007-05-21 2017-01-17 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
AU2002950779A0 (en) * 2002-08-15 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of immunomodulation
EP1422241A1 (en) 2002-11-19 2004-05-26 Alexander Steinkasserer Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
DE60334246D1 (en) * 2002-11-21 2010-10-28 Celltech R & D Inc MODULATE IMMUNE RESPONSES
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
US7169898B2 (en) 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
US8227437B2 (en) * 2006-06-22 2012-07-24 Tai June Yoo Restoration of hearing loss
WO2008098787A2 (en) * 2007-02-16 2008-08-21 Helmholtz-Zentrum für Infektionsforschung GmbH Cd83 as a molecular switch for the induction of regulatory (immunosuppressive) t-cells
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
DK2164514T3 (en) 2007-05-21 2017-02-27 Alderbio Holdings Llc Antibodies to IL-6 and its use
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
WO2008144753A2 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to tnf alpha and use thereof
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US8513208B2 (en) * 2008-02-28 2013-08-20 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2012138377A2 (en) * 2010-10-01 2012-10-11 Trustees Of The University Of Pennsylvania The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
CN103687611A (en) 2011-03-11 2014-03-26 阿德瓦希斯公司 Listeria-based adjuvants
JP2013040160A (en) * 2011-07-01 2013-02-28 Genentech Inc Use of anti-cd83 agonist antibody for treating autoimmune disease
JP2013150592A (en) * 2011-07-01 2013-08-08 Genentech Inc Use of anti-cd83 agonist antibody for treating autoimmune disease
SG10201700392UA (en) 2012-03-12 2017-03-30 Advaxis Inc Suppressor cell function inhibition following listeria vaccine treatment
CA2899960C (en) 2013-02-01 2022-05-03 Transbio Ltd Anti-cd83 antibodies and use thereof
MX2016010059A (en) * 2014-02-04 2017-04-27 Contrafect Corp Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof.
US10870704B2 (en) 2014-10-23 2020-12-22 Kira Biotech Pty Limited CD83 binding proteins and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316920A (en) * 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
WO2002074921A2 (en) * 2001-03-19 2002-09-26 Cellular Genomics Inc. Methods for isolating proteins expressed by dendritic cells
WO2003038072A1 (en) * 2001-10-31 2003-05-08 Universite Libre De Bruxelles Generation and use of new types of dendritic cells
WO2003040170A2 (en) * 2001-11-09 2003-05-15 Pfizer Products Inc. Antibodies to cd40

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316320A (en) * 1992-03-18 1994-05-31 Corrosion Control Corp. Isolation gasket for critical service flow line applications
US5710262A (en) 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides
WO1997029781A1 (en) * 1996-02-15 1997-08-21 Immunex Corporation Methods and compositions for modulating an immune response
US6900016B1 (en) * 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316920A (en) * 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
WO2002074921A2 (en) * 2001-03-19 2002-09-26 Cellular Genomics Inc. Methods for isolating proteins expressed by dendritic cells
WO2003038072A1 (en) * 2001-10-31 2003-05-08 Universite Libre De Bruxelles Generation and use of new types of dendritic cells
WO2003040170A2 (en) * 2001-11-09 2003-05-15 Pfizer Products Inc. Antibodies to cd40

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1480598A4 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8999330B2 (en) 2007-05-21 2015-04-07 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9241990B2 (en) 2007-05-21 2016-01-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRIP
US9546213B2 (en) 2007-05-21 2017-01-17 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9085615B2 (en) 2008-11-25 2015-07-21 Alderbio Holdings Llc Antibodies to IL-6 to inhibit or treat inflammation
US9187560B2 (en) 2008-11-25 2015-11-17 Alderbio Holdings Llc Antagonists of IL-6 to treat cachexia, weakness, fatigue, and/or fever
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9265825B2 (en) 2008-11-25 2016-02-23 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US9468676B2 (en) 2009-11-24 2016-10-18 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8992908B2 (en) 2010-11-23 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of oral mucositis
US9304134B2 (en) 2010-11-23 2016-04-05 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of anemia

Also Published As

Publication number Publication date
US7850968B2 (en) 2010-12-14
US20110144309A1 (en) 2011-06-16
WO2003045318A2 (en) 2003-06-05
CA2466845A1 (en) 2003-06-05
US20100081797A1 (en) 2010-04-01
AU2002357759A8 (en) 2003-06-10
JP2005519586A (en) 2005-07-07
EP1480598A4 (en) 2006-03-22
EP1480598A2 (en) 2004-12-01
US20060083740A1 (en) 2006-04-20
US7618629B2 (en) 2009-11-17
AU2002357759A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
WO2003045318A3 (en) Manipulation of cytokine levels using cd83 gene products
WO2001019981A3 (en) Functional genomics using zinc finger proteins
WO1999041368A3 (en) Optimization of immunomodulatory properties of genetic vaccines
WO2000029582A3 (en) Cell surface receptor antigen vaccines
AU3143795A (en) Isoamylase gene from flaviobacterium sp., compositions containing it and methods using it
WO2003014347A3 (en) Plant seed specific promoters
WO2005044976A3 (en) Oligomeric compounds for use in gene modulation
WO2004048552A3 (en) Modulating immune responses
AU3725697A (en) Infectious papillomavirus pseudoviral particles
EP0579360A3 (en) Hyperthermophiles alpha-amylase gene.
AU762955C (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase SRC
WO2000058352A3 (en) Barley gene for thioredoxin and nadp-thioredoxin reductase
EP1010761A4 (en) Gene
WO2003033738A3 (en) Polymorphic marker that can be used to assess the efficacy of interferon therapy
EP1908835A3 (en) Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switches
AU1284501A (en) Method for modulating nitrilase selectivity, nitrilases obtained by said method and use thereof
WO1998054344A3 (en) Modulators of morphogen expression and methods of identifying the same
AU1469600A (en) Nucleic acids encoding transferrin receptor-like proteins and products related thereto
WO1999055847A3 (en) Enzymatic nucleic acids molecules which modulate the expressions and/or replication of hepatitis c virus
WO2003012103A3 (en) Nucleic acids coding for novel fbox proteins, their diagnostic and therapeutic uses
AU7099400A (en) Methods and reagents for regulating gene expression
AU3604800A (en) Method for regulating the stability of recombinant proteins, and antibodies and products useful therein
AU6408196A (en) Genetic therapy employing the hhv-6a derived ts gene or polypeptide
AU2002237216A1 (en) Screening method for the selection of peptides or proteins comprising discrete dimension assays, gene mutation and application assays
EP1518927A3 (en) Optimization of immunomodulatory properties of genetic vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10719642

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2466845

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003546823

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002792297

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002792297

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006083740

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10496284

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10496284

Country of ref document: US